Last update 26 Nov 2024

Denocabtagene Ciloleucel

Overview

Basic Info

Drug Type
CAR-T
Synonyms
CAR-T-19-DNR(Immunotech Biopharm Ltd.), CAR-T–19-D2, CAR-T–19-DNR
+ [1]
Target
CD19 x TGF-β2
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), TGF-β2 inhibitors(Transforming growth factor beta 2 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
CD19 positive Diffuse Large B-Cell LymphomaCD19-positive B-cell acute lymphoblastic leukemia
Inactive Indication-
Originator Organization
Immunotech Biopharm LtdImmunotech Biopharm Ltd
Active Organization
Beijing Yongtai Ruike Biotechnology Co. Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with Denocabtagene Ciloleucel
CTR20232733 / RecruitingPhase 1
迪诺仑赛注射液（或RC19D2细胞注射液）治疗CD19阳性复发或难治性弥漫大B细胞淋巴瘤Ⅰ期临床试验
[Translation] Phase I clinical trial of Denolan injection (or RC19D2 cell injection) for the treatment of CD19-positive relapsed or refractory diffuse large B-cell lymphoma
NCT06047197 / RecruitingPhase 1
Phase I Clinical Trial of Dinorencel Injection (or RC19D2 Cell Injection) in the Treatment of CD19-positive Relapsed or Refractory Diffuse Large B-cell Lymphoma
CTR20210591 / RecruitingPhase 1
CAR-T-19（抗CD19单链抗体嵌合抗原受体T细胞）注射液治疗25岁（含）以下CD19阳性复发/难治B细胞急性淋巴细胞白血病的单臂、开放的Ⅰ期临床研究
[Translation] A single-arm, open-label phase I clinical study of CAR-T-19 (anti-CD19 single-chain antibody chimeric antigen receptor T cell) injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia in patients under 25 years of age (inclusive)
100 Clinical Results associated with Denocabtagene Ciloleucel
Login to view more data
100 Translational Medicine associated with Denocabtagene Ciloleucel
Login to view more data
100 Patents (Medical) associated with Denocabtagene Ciloleucel
Login to view more data
100 Deals associated with Denocabtagene Ciloleucel
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD19 positive Diffuse Large B-Cell LymphomaPhase 1
CN
Beijing Yongtai Ruike Biotechnology Co. Ltd.
05 Sep 2023
CD19-positive B-cell acute lymphoblastic leukemiaPhase 1
CN
Beijing Yongtai Ruike Biotechnology Co. Ltd.
07 Jun 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free